Visit Website →
← Back to blog

PGx Program Metrics: What Your Lab Should Track and Report

October 30, 2026
PGx Program Metrics: What Your Lab Should Track and Report

A pharmacogenomics program is easy to launch and surprisingly hard to defend at budget time. The labs that keep their programs funded track a short, disciplined set of metrics in three groups: operational (how fast and how reliably reports leave your lab), adoption (whether clinicians order tests and act on them), and clinical and financial impact (whether medication decisions change and whether the program pays for itself over a realistic horizon). This guide walks through each group, shows how to build an ROI model that survives scrutiny, and explains how deployment timing affects when each number becomes meaningful.

SignalPGx
Make PGx Reporting Easier to Measure
SignalPGx turns genotype and medication data into physician-reviewed reports, helping laboratories support consistent PGx reporting.
Explore SignalPGx

TL;DR

  • Track three layers: operational (turnaround, report quality), adoption (test uptake, recommendation follow-through, therapy modifications), and impact (adverse events, cost).
  • Build ROI on cash flow, break-even, and net present value across at least five years, and state your time horizon openly.
  • Published results show what is achievable: one hospital moved from 31% of reports within 2 days to 99% within 2 days in three years.
  • Report limitations alongside results: soft costs are hard to quantify and adverse-event recording varies from site to site.
  • Deployment speed determines how soon you can begin collecting baseline data, so measure from day one of go-live, not from the first quarterly review.

Table of Contents

Why metrics decide whether a PGx program survives

Most laboratory directors can describe what a pharmacogenomic report does clinically. Fewer can show a finance committee what the program did last quarter. The difference matters because PGx programs sit between disciplines: the lab produces the report, the prescriber acts on it, and the benefit shows up in pharmacy spend, adverse event rates, or length of stay, none of which your lab owns.

A useful metric set therefore does two jobs. It tells your team whether the reporting service is running well, and it gives clinical and executive stakeholders a reason to keep ordering. A 2025 scoping review of hospital pharmacogenetic programs recommends tracking test uptake, how often recommendations are followed, and therapy modifications, and notes that active physician engagement is needed for results to enter clinical decisions. That single finding shapes the rest of this article: the lab's own numbers are necessary but never sufficient.

Operational metrics: how your lab performs

Operational metrics are the ones you control completely, so start there. They are also the ones prescribers notice first, because a late report is a report that arrives after the prescription has been written.

Turnaround time

Turnaround time (TAT) should be measured from sample receipt to released report, and again from release to delivery in the clinician's workflow. Two published figures give you a sense of the range:

The point of the second example is the metric design. Rather than a single average, the hospital tracked the share of reports delivered inside a clinically meaningful window. Percentages inside a target window are harder to hide behind than means, and they show improvement over time clearly. Report both the median and the percentage within target, and break them out by drug-gene pair, because a pre-emptive panel and a single-gene urgent request have different clocks.

Report quality and rework

Turnaround means little if reports bounce back. Track:

  • Rework rate: the share of reports reopened after medical director review.
  • Review time: how long a report waits for sign-out, since this is usually the largest controllable delay.
  • Evidence currency: how many released reports reflect the guideline version in force on the release date. Manual guideline tracking is where drift appears, and it is worth measuring even if the answer is uncomfortable.
  • Audit completeness: whether every released report has a traceable reviewer, timestamp, and evidence snapshot.

These are lab-side measures that also support compliance conversations, which matter for any program handling patient genotype data under HIPAA.

Adoption metrics: whether clinicians use what you produce

Adoption is where programs quietly fail. A lab can deliver fast, accurate reports that nobody acts on.

Test utilization

Utilization is the most direct signal of provider confidence. In the same tertiary hospital study, test utilization rose 2.2-fold in 2019 and 2.7-fold in 2020 compared with earlier baselines, which the authors read as growing provider adoption. Track orders per month by ordering department and by prescriber, so you can see whether growth is broad or driven by two enthusiastic clinicians.

Recommendation follow-through and therapy modification

Follow-through asks: when a report says to consider an alternative or adjust a dose, what happened next? Therapy modification asks the simpler question of whether a prescription changed at all. Both are named in the 2025 scoping review as core evaluation items. They require a data link back from the medication record, which is one reason EHR integration is a metric enabler as much as a convenience. If you are mapping your first interface, our walkthrough on mapping one gene-drug pair in FHIR first shows a way to scope it so that the follow-through data comes along with the report.

Specialty spread

The same review found that psychiatry accounted for 26% and oncology for 16% of hospital program implementations, while 19% of studies described programs spanning multiple specialties. For your own program, a useful adoption metric is the number of specialties placing orders. A program living in one department is fragile; one spread across several is harder to cut.

Reported PGx program distribution across specialties

Clinical impact: did medication decisions improve?

This is the hardest category, and honesty about the difficulty is part of the work. There is no single accepted outcome metric for laboratory-reported PGx, and we have found no standard that every program uses. What labs can do is build a chain of evidence from the report to the decision to the outcome, measuring each link you can reach.

A practical chain looks like this:

  1. Actionable result rate: the share of reports containing at least one result that triggers a guideline recommendation.
  2. Decision change rate: among actionable results, the share where the prescriber changed drug or dose.
  3. Targeted adverse event tracking: for a small number of high-impact drug-gene pairs, compare local adverse event rates before and after the program.
  4. Process safety checks: for example, the share of patients with a CYP2C19 poor metabolizer result who were not discharged on clopidogrel. Our clinician actions guide for CYP2C19 poor metabolizers describes the prescribing decision this metric audits.

Choosing a small formulary matters here. A 2025 expert perspective advises services to define a formulary of high-impact drug-gene pairs, integrated decision support guardrails, and dashboards shared across directorates to monitor safety and equity. Measuring forty pairs shallowly produces noise. Measuring four pairs well, such as clopidogrel and CYP2C19, codeine and CYP2D6, tacrolimus and CYP3A5, or irinotecan and UGT1A1, produces a story. We cover each in detail in our guides on clopidogrel and CYP2C19, codeine and CYP2D6, and tacrolimus and CYP3A5.

When you compare adverse event rates, compare them against a reference. Duke-hosted guidance on measuring PGx cost effectiveness advises comparing local adverse-event rates with national averages and quantifying both hard and soft costs.

A starting dashboard

The table below groups a workable first-year dashboard. Choose the rows your data systems can actually support; a metric you cannot refresh monthly will be abandoned.

LayerMetricDefinitionReview cadence
OperationalMedian TATSample receipt to released reportMonthly
OperationalPercent within targetReports released inside your clinical window, such as 2 daysMonthly
OperationalSign-out waitTime from draft to medical director approvalMonthly
OperationalEvidence currencyReports reflecting current guideline versionQuarterly
AdoptionOrders by departmentTest volume per ordering unit and prescriberMonthly
AdoptionFollow-throughActionable results with a documented responseQuarterly
AdoptionTherapy modificationsPrescriptions changed after a reportQuarterly
ImpactTargeted adverse eventsLocal rate for selected drug-gene pairs against a referenceSemiannual
FinancialCost per reportDirect lab cost plus review laborQuarterly

Modeling PGx program ROI for a laboratory

Readers asking about ROI usually want one number. The honest answer is a model with stated assumptions. The Duke-hosted guidance recommends that financial planning for a laboratory PGx program include cash flow, break-even analysis, net present value, and cumulative income over a minimum five-year period. A five-year view matters because the first year carries setup, validation, and education costs while volume is still ramping.

Costs to include

  • Setup: assay validation, informatics, interface build, and the strategy and design work that precedes them.
  • Recurring: reagents, instrument time, medical director review labor, software subscription, and compliance maintenance.
  • Soft costs: clinician education, committee time, and support requests. These are hard to price, and the same guidance flags them as a known difficulty, so list them even when you can only estimate.

Revenue and savings to include

  • Test revenue: this depends on payer coverage, so build it from your actual reimbursement experience. Our laboratory billing guide on pharmacogenomics reimbursement covers the inputs.
  • Avoided downstream cost: adverse events and ineffective prescribing that your health system avoids. These usually accrue to the hospital or payer rather than the lab, so a lab-only ROI and a system-level ROI are different calculations. Say which one you are showing.

What published evidence suggests

Published figures are useful for sanity-checking, not for substituting into your model. One review reports PGx-guided therapy savings of up to $3,962 per patient annually even after test costs, and found that among antidepressant and antipsychotic studies, 50% were cost-effective and 39% were cost-saving. Note what that implies: a meaningful share were neither.

Results also vary by drug-gene pair. A 2022 decision-analytic model from the Netherlands found that irinotecan-UGT1A1 guidance was cost-saving, with €481,000 saved in drug costs, while clopidogrel-CYP2C19 increased drug costs by €2.8 million. The lesson for a lab is to model by pair rather than assume the whole panel behaves alike. If your program includes irinotecan, our guide to UGT1A1 reporting for irinotecan labs describes what a launch involves.

Cohort-building efficiency can also enter an ROI case for programs tied to research. A comparison of EMR-linked biobank studies with traditional grant-funded pharmacogenomic studies found a median cost per genotyped subject of $393 versus $1,419, with a median 0.25 years to identify subjects against 3 years. That is a research-cost finding, so use it only if your program has a research arm.

Outside the United States, a 2026 Mexican study estimated that a hypothetical 10 to 30% reduction in preventable adverse drug reaction hospitalizations could save roughly $1,111 to $3,333 million MXN annually in that country's public system. It is a national projection, not a benchmark for an individual lab.

What published evidence suggests — overview diagram

Deployment timeline: when metrics start to mean something

The timeline question is really a measurement question: how soon can you begin collecting clean baseline data? Deployment follows recognizable phases. A hospital implementation review describes evaluating evidence and selecting actionable drug-gene pairs, choosing a testing strategy, and planning result reporting with IT, ideally through EHRs and clinical decision support, with the pharmacy and therapeutics committee monitoring the program for improvement.

PhaseWhat happensMetric implication
PlanningSelect drug-gene pairs, define governanceSet targets and baselines before launch
ValidationConfirm assay and interpretation logicRecord rework and discordance rates
IntegrationConnect to the LIS and EHREnable follow-through and modification tracking
LaunchGo live with a limited formularyBegin TAT and uptake measurement
OptimizationExpand pairs, retire weak onesReview impact and ROI against the model

What drives the calendar? Most of the time is rarely the lab bench. The U-PGx consortium concluded that technical feasibility is achievable, while adoption is mainly held back by fragmented health IT infrastructure and the need for harmonized international guidelines. Culture matters too: a review of 40 pharmacogenetic programs, of which 26 (66%) were in the United States, named positive institutional culture, active leadership engagement, stakeholder education, and clinical champions as common facilitators. A pharmacy-led, multidisciplinary committee is another recommended structure, per the 2025 expert perspective.

We have not found a published industry-wide figure for how many weeks a PGx program takes, and we would be wary of anyone who quotes one without defining scope. For the reporting layer specifically, we can speak to our own platform: white-label deployments typically go live in 5 to 7 days. That covers report infrastructure, not assay validation, committee approval, or interface testing at your hospital partners, which run on their own schedules. A practical checklist helps keep those parallel tracks honest; see our CPIC implementation checklist.

Perspective: measure what changes a decision

We see the same pattern across laboratories. Teams collect many numbers that describe the lab and few that describe the prescriber. Our view is that every PGx dashboard should be built backward from one question: what did a clinician do differently because of this report?

That view shapes how we build. Reports are physician-reviewed, with an audit trail, so that review time and rework are measurable from the first week rather than reconstructed later. Living reanalysis means recommendations update as guidelines evolve, which turns evidence currency from a periodic audit into a standing property of the report. And HL7/FHIR integration matters to us less as a connectivity feature than as the path by which follow-through data returns to your lab.

We also believe in reporting small. Pick a handful of drug-gene pairs, define success before launch, and publish the results internally, including the disappointing ones. A program that shows a clopidogrel cost increase honestly is more credible than one that claims every pair saves money. Clinicians stay in control of final approval, and your metrics should reflect that partnership between lab, medical director, and prescriber.

— Tarek

Limitations to disclose with your numbers

A metrics report that hides its weaknesses invites distrust. Three limitations deserve a standing footnote.

Soft costs resist quantification. Education, committee time, and support effort are real, and the Duke-hosted guidance lists difficulty quantifying soft costs and variation in adverse-event recording accuracy among the limitations. If one unit codes adverse events carefully and another does not, before-and-after comparisons can mislead.

Time horizon changes the answer. Van der Wouden and colleagues caution that cost-effectiveness results for pharmacogenomics can be heavily influenced by the chosen time horizon, and that ignoring the long-term cost of alternative drugs for lifelong conditions can understate total costs. State your horizon beside every ROI figure.

Attribution is partial. Some savings land in pharmacy or inpatient budgets, and a prescriber may change a drug for reasons unrelated to the report. Describe associations as associations, and where you can, use a comparison group or a pre-launch baseline.

How SignalPGx supports program measurement

We build SignalPGx as white-label reporting infrastructure for clinical, molecular diagnostic, hospital, and reference laboratories. Reports combine genotype data, medication history, and evidence from more than 15 sources, with medical director review and an audit trail, delivery to patients and providers, and HL7/FHIR integration. Those features create the data your dashboard needs: timestamps for every review step, a record of the evidence behind each recommendation, and a channel back from the EHR.

SignalPGx

If you are scoping a program, our White-Label PGx Reporting page describes the Pilot, Standard, Scale, and Enterprise plans. For planning support, Discovery & Strategy starts from $7,000 as a one-off project, System Design from $9,000, and Deployment & Integration from $15,000. Our team can help you define the metric set and baseline before the first report goes out.

FAQ

What are the most important PGx program metrics to start with?

Begin with percent of reports released within your target window, test orders by department, and the share of actionable results where a prescriber changed therapy. These three cover operations, adoption, and decision impact. Add adverse event tracking for one or two high-impact drug-gene pairs once your data pipeline is stable.

How long should I model PGx ROI for?

Use at least five years. Published planning guidance recommends cumulative income and NPV over a minimum five-year period, because early years carry setup costs and ramping volume. Show shorter horizons too, labeled as such.

Does PGx testing always save money?

No. A review of antidepressant and antipsychotic studies found that 50% were cost-effective and 39% were cost-saving, and a Dutch model found savings for irinotecan-UGT1A1 but higher drug costs for clopidogrel-CYP2C19. Results depend on the drug-gene pair, population, and time horizon.

How quickly can a lab deploy PGx reporting?

The reporting layer on our platform typically goes live in 5 to 7 days. The full program takes longer, because drug-gene pair selection, committee approval, validation, and EHR interface testing run on your institution's schedule. Health IT fragmentation is a commonly reported barrier, so start interface planning early.

Who should own PGx metrics?

Share ownership. The lab owns operational metrics, while a pharmacy-led multidisciplinary committee is well placed to own adoption and impact, as a 2025 expert perspective recommends. Dashboards shared across departments keep everyone looking at the same numbers.

Sources